Eupraxia reports positive Phase 1b/2a trial data for EP-104GI in treating eosinophilic esophagitis.

Eupraxia Pharmaceuticals announced encouraging data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data showed that patients receiving 20 injections of EP-104GI experienced significant improvements in the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), indicating reduced inflammation and fibrosis in the esophagus. This dosing regimen is now being studied in the placebo-controlled Phase 2b trial, with top-line results expected in Q4 2026. These findings suggest EP-104GI could offer a promising new treatment for EoE, a condition causing esophageal inflammation and swallowing difficulties.